Literature DB >> 25572645

Emergency neurosurgical care in patients treated with apixaban: report of 2 cases.

Christopher Beynon1, Anna Potzy2, Andreas W Unterberg2, Oliver W Sakowitz2.   

Abstract

A debate has emerged regarding the safety profile of direct anticoagulants, which are increasingly prescribed for the prevention of thromboembolic events. Despite favorable safety data derived from controlled clinical trials, the absence of specific antidotes for the management of hemorrhagic complications represents a major challenge for emergency physicians. Here, we present the first report on patients treated with the direct factor Xa inhibitor apixaban and conditions requiring urgent neurosurgical intervention (intracerebral hemorrhage, n = 1; subdural hematoma, n = 1). Prothrombin complex concentrates were administered before surgery, and both patients had a favorable postsurgical course without bleeding or thromboembolic complications. Further studies are needed, but this approach seems to be suitable for the emergency management of apixaban-associated intracranial hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25572645     DOI: 10.1016/j.ajem.2014.12.017

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Authors:  Maureane Hoffman; Joshua N Goldstein; Jerrold H Levy
Journal:  Int J Emerg Med       Date:  2018-12-03

Review 2.  Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal.

Authors:  Jerrold H Levy; James Douketis; Thorsten Steiner; Joshua N Goldstein; Truman J Milling
Journal:  Anesthesiology       Date:  2018-12       Impact factor: 7.892

Review 3.  Apixaban-induced subdural bleeding: case presentation and literature review.

Authors:  Eman Alayad; Sami Khairy; Ahmed Aloraidi
Journal:  BMJ Case Rep       Date:  2018-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.